SCHEMBL3199108

SCHEMBL3199108

NCCc1cn(S(=O)(=O)c2ccc3c(c2)OCC(=O)N3)c2ccc(Cl)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
HTR6 P50406 10/20 0.40
TSHR P16473 1/20 0.39
PKM P14618 1/20 0.35
HTR1A P08908 1/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35
DRD4 P21917 1/20 0.35
HTR2A P28223 1/20 0.35
ADRA1B P35368 1/20 0.35
DRD3 P35462 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
POLB P06746 1/20 0.34
GAA P10253 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
IDH1 O75874 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3212533 0.85 LMNA (0.42) LMNAHTR6TSHRPKMHTR1A
SCHEMBL3203402 0.78 PPARG (0.47) HTR6PKMCHRM5
SCHEMBL3202550 0.78 PKM (0.45) HTR6PKMHTR1APOLBGAA
SCHEMBL3201767 0.75 HTR6 (0.59) HTR6
SCHEMBL3202419 0.74 HTR6 (0.60) HTR6HTR1AADRA2ADRD2HTR2A
SCHEMBL3199222 0.74 LMNA (0.42) LMNAHTR6TSHRPKMHTR1A
SCHEMBL3204972 0.74 HTR6 (0.43) LMNAHTR6TSHRHTR1ADRD2
SCHEMBL3215153 0.73 HTR6 (0.52) HTR6HTR1AHTR2ADRD3
SCHEMBL3201042 0.72 HTR6 (0.50) HTR6
SCHEMBL3209934 0.69 HTR6 (0.38) HTR6HTR1AADRA2AHTR2AADRA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US claimed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-02-04 US disclosed
WO-2010011546-A2 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY MEMORY PHARMACEUTICALS CORPORATION (US) 2010-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029629-A1 ACYCLIC COMPOUNDS HAVING 5-HT6 RECEPTOR AFFINITY HTR6, HTR1A, HTR5A LMNA 2649/4885HTR6 1/4885TSHR 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.